Stifel Downgrades HilleVax to Hold After HIL-214 Norovirus Vaccine Candidate Discontinuation

Tuesday, 9 July 2024, 16:52

Stifel downgrades HilleVax to hold and lowers price target to $3 as the company discontinues the development of its norovirus vaccine candidate HIL-214 for infants. The decision follows the news of the failed study, impacting the company's outlook in the pharmaceutical sector.
Seeking Alpha
Stifel Downgrades HilleVax to Hold After HIL-214 Norovirus Vaccine Candidate Discontinuation

Stifel Downgrades HilleVax to Hold

Stifel has lowered its rating on HilleVax (HLVX) to hold after the company's announcement of discontinuing the development of its norovirus vaccine candidate HIL-214 for infants.

Study Failure and Price Target

  • Impact on Stock Rating: Downgraded to hold
  • Price Target Adjustment: Reduced to $3
  • Reason: Discontinuation of HIL-214

This decision reflects the concerns surrounding the failed study and its repercussions on HilleVax's future prospects in the pharmaceutical industry.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe